A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 1,000 shares of ALNY stock, worth $286,910. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,000
Previous 200 400.0%
Holding current value
$286,910
Previous $48,000 472.92%
% of portfolio
0.02%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$233.81 - $287.01 $187,048 - $229,608
800 Added 400.0%
1,000 $275,000
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $83,124 - $139,200
-600 Reduced 75.0%
200 $40,000
Q2 2022

Aug 16, 2022

SELL
$120.42 - $169.29 $132,462 - $186,219
-1,100 Reduced 57.89%
800 $117,000
Q2 2021

Jul 13, 2021

BUY
$128.63 - $176.89 $77,178 - $106,133
600 Added 46.15%
1,900 $322,000
Q4 2019

Jan 28, 2020

BUY
$74.51 - $124.23 $37,255 - $62,115
500 Added 62.5%
1,300 $150,000
Q3 2018

Oct 26, 2018

SELL
$87.52 - $122.67 $105,024 - $147,204
-1,200 Reduced 60.0%
800 $70,000
Q1 2018

Apr 11, 2018

BUY
$115.92 - $148.54 $81,144 - $103,978
700 Added 53.85%
2,000 $2.19 Million
Q4 2017

Jan 18, 2018

BUY
$114.49 - $139.98 $148,837 - $181,974
1,300
1,300 $165,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $35.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.